All In Biotech

Drug Trial Radar · NCT00268476

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial

Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 11,992 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

11,992

Actual

Start

Jul 8, 2005

Primary completion

Mar 2026

Study completion Dec 2030

Sponsor

Lead sponsor
Medical Research CouncilGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Dec 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer. This trial aims to see if we can improve the way in which prostate cancer is currently managed, either by adding new treatments to the standard approach or by modifying the type of hormone therapy aiming to improve quality-of-life by reducing the side effects of treatment. Each new treatment approach is compared against a control arm receiving the current standard treatments. We aim to identify treatment strategies that enable men to live longer, or as long but with an improved quality-of-life, as well as offering value for money for the health service. Since opening to accrual in Oct-2005, the trial has tested many ways of treating prostate cancer and some results are now already known. More than 10,000 men will join the trial with answers becoming available throughout the trial. New patients joining the trial from Protocol version 17.0 onwards (activated in December 2018) may be eligible to join one of two treatment comparisons, metformin (treatment group K; the "metformin comparison") and transdermal oestradiol (treatment group L; the "transdermal oestradiol comparison"). A computer program will be used to allocate which treatment each participant receives, using a chance process. Summary of the research arms in STAMPEDE trial platform Summary of research treatment groups currently open to recruitment (June 2017) 1. Metformin (Arm K): This anti-diabetic medication is proposed to have both anti-cancer effects and may help prevent the adverse metabolic effects of long-term ADT. STAMPEDE will investigate whether adding metformin to the current standard-of-care for non-diabetic men can improve all-cause survival. 2. Transdermal oestradiol (Arm L): This is an alternative form of hormone treatment which has been shown to suppress testosterone as effectively as standard ADT and avoid some of the side-effects. It may also help to avoid the adverse metabolic effects and fatigue and therefore improve overall quality of life compared with standard forms of ADT. STAMPEDE will investigate whether transdermal oestradiol can treat the cancer as well as current standard forms of ADT. 3. Control group (Arm A): Patients allocated to this group receive the current standard-of-care ADT +/- RT +/- docetaxel.

Conditions

  • Prostate Cancer

Interventions

  • CelecoxibDrug

  • DocetaxelDrug

  • PrednisoloneDrug

  • ADTDrug

  • Zoledronic AcidDrug

  • AbirateroneDrug

  • Radiotherapy to the prostateRadiation

  • EnzalutamideDrug

  • MetforminDrug

  • Transdermal OestradiolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: 1:Not applicable

Locations

120 sites in 2 countries. Site status is shown where the registry gives one.

  • Hirslanden Klinik Aarau

    Aarau, Switzerland

  • Universitaetsspital-Basel

    Basel, Switzerland

  • Inselspital Bern

    Bern, Switzerland

  • Liestal Hospital

    Liestal, Switzerland

  • Kantonsspital - St. Gallen

    Sankt Gallen, Switzerland

  • UniversitaetsSpital Zuerich

    Zurich, Switzerland

  • City Hospital Triemli

    Zurich, Switzerland

  • Lausanne Centre Hospitalier Universitaire

    Lausanne, Canton of Vaud, Switzerland

  • Winterthur Hospital

    Winterthur, Canton of Zurich, Switzerland

  • Kantonsspital Graubuenden

    Chur, Kanton Graubünden, Switzerland

  • Barnet General Hospital

    Barnet, United Kingdom

  • Colchester General Hospital

    Colchester, United Kingdom

  • Forth Valley Hospital

    Larbert, United Kingdom

  • Lincoln Hospital

    Lincoln, United Kingdom

  • North Tees Hospital

    Stockton-on-Tees, United Kingdom

  • New Cross Hospital

    Wolverhampton, United Kingdom

  • Berkshire Cancer Centre at Royal Berkshire Hospital

    Reading, Berkshire, United Kingdom

  • Royal Bolton Hospital

    Farnworth, Bolton, United Kingdom

  • Wycombe General Hospital

    High Wycombe, Buckinghamshire, United Kingdom

  • Addenbrooke's Hospital

    Cambridge, Cambridgeshire, United Kingdom

  • Broomfield Hospital

    Broomfield, Chelmsford, United Kingdom

  • Countess of Chester Hospital

    Chester, Chesire, United Kingdom

  • James Cook University Hospital

    Middlesbrough, County Durham, United Kingdom

  • Cumberland Infirmary

    Carlisle, Cumbria, United Kingdom

  • North Devon District Hospital

    Barnstaple, Devon, United Kingdom

  • Royal Devon and Exeter Hospital

    Exeter, Devon, United Kingdom

  • Royal Bournemouth Hospital

    Bournemouth, Dorset, United Kingdom

  • Dorset County Hospital

    Dorchester, Dorset, United Kingdom

  • Poole Hospital

    Poole, Dorset, United Kingdom

  • Castle Hill Hospital

    Cottingham, East Riding Of Yorkshire, United Kingdom

  • Eastbourne District General Hospital

    Eastbourne, East Sussex, United Kingdom

  • Conquest Hospital

    Saint Leonards-on-Sea, East Sussex, United Kingdom

  • William Harvey Hospital

    Ashford, England, United Kingdom

  • Stoke Mandeville Hospital

    Aylesbury, England, United Kingdom

  • Basingstoke and North Hampshire NHS Foundation Trust

    Basingstoke, England, United Kingdom

  • City Hospital (Birmingham)

    Birmingham, England, United Kingdom

  • Sussex Cancer Centre at Royal Sussex County Hospital

    Brighton, England, United Kingdom

  • Burnley General Hospital

    Burnley, England, United Kingdom

  • Queen's Hospital

    Burton-on-Trent, England, United Kingdom

  • West Suffolk Hospital

    Bury St Edmunds, England, United Kingdom

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.